Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

hydroxychloroquine

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Immunomodulator, Phospholipase A2 inhibitor

Related drugs:

‹

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

hydroxychloroquine MDT (0)

icosapent ethyl (0)

quaratusugene ozeplasmid (3)

SQZ-AAC-HPV (1)

HLA-matched donor mononuclear enriched leukocytes (0)

rimiducid activated rivogenlecleucel (0)

GB221 (trastuzumab biosimilar) (0)

GSK2302024A (0)

MVA-BN-HER2 (0)

84AA-API 14AA (0)

nelipepimut-S (0)

engineered donor allograft cell therapy (0)

parvovirus H-1 (0)

FT1050+FT4145 programmed mPB (0)

allodepleted T-cell immunotherapeutics (0)

TAEK-VAC-HerBy vaccine (0)

Undisclosed CISH inactivated TIL (0)

alpha-tocopheroloxyacetic acid (0)

thymalfasin (0)

chlorogenic acid (0)

dendritic cell activation therapy (0)

minocycline (0)

hydroxychloroquine MDT (0)

icosapent ethyl (0)

›

SMAD4 deletion	Pancreatic Adenocarcinoma	SMAD4 deletion	Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive : C3	gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive: C3 – Early Trials gemcitabine + albumin-bound paclitaxel + hydroxychloroquine Sensitive : C3
KRAS G12D + STK11 mutation	Lung Cancer	KRAS G12D + STK11 mutation	Lung Cancer	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D
GNA11 Q209L	Uveal Melanoma	GNA11 Q209L	Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D
GNAQ Q209P	Uveal Melanoma	GNAQ Q209P	Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D	trametinib + hydroxychloroquine Sensitive: D – Preclinical trametinib + hydroxychloroquine Sensitive : D
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D
Chr del(11q)	Chronic Lymphocytic Leukemia	Chr del(11q)	Chronic Lymphocytic Leukemia	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D	hydroxychloroquine Sensitive: D – Preclinical hydroxychloroquine Sensitive : D